Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study

Endocrine

Volumn 47, Issue 2, 2014, Pages 456-462

  Pepe, J ^a   Isidori, A M ^b   Falciano, M ^c   Iaiani, G ^c   Salotti, A ^c   Diacinti, D ^a   Del Fiacco, R ^a   Sbardella, E ^b   Cipriani, C ^a   Piemonte, S ^a   Raimo, O ^a   Biondi, P ^a   Biamonte, F ^a   Lenzi, A ^b   Minisola, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bisphosphonates; HIV; Hypogonadism; Osteoporosis; Risedronate

Indexed keywords

CALCIUM; COLECALCIFEROL; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; TESTOSTERONE;

ADULT; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOGONADISM; MALE; OSTEOPOROSIS; PILOT STUDY; SPINE FRACTURE; TREATMENT OUTCOME; AGED; ANALOGS AND DERIVATIVES; BLOOD; BONE DISEASES, METABOLIC; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; LUMBAR VERTEBRA; MIDDLE AGED; OSTEOPOROTIC FRACTURES;

ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCIUM; CHOLECALCIFEROL; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; HIV INFECTIONS; HUMANS; HYPOGONADISM; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PILOT PROJECTS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84911002363     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0349-0     Document Type: Article

References (30)

1. C. Cazanave, M. Dupon, V. Lavignolle-Aurillac, N. Barthe, S. Lawson-Ayayi, N. Mehsen, P. Mercié, P. Morlat, R. Thiébaut, F. Dabis, Groupe d’epidémiologie clinique du SIDA en aquitaine, Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 22, 395–402 (2008)
2. C. Torti, G. Mazziotti, P.A. Soldini, E. Focà, R. Maroldi, D. Gotti, G. Carosi, A. Giustina, High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 41, 512–517 (2012)
3. V. Rochira, L. Zirilli, G. Orlando, D. Santi, G. Brigante, C. Diazzi, F. Carli, C. Carani, G. Guaraldi, Premature decline of serum total testosterone in HIV-infected men in the HAART-era. PLoS One 6, e28512 (2011)
4. D.M. Wunder, N.A. Bersinger, C.A. Fux, N.J. Mueller, B. Hirschel, M. Cavassini, L. Elzi, P. Schmid, E. Bernasconi, B. Mueller, H. Furrer, Swiss HIV Cohort Study, Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir. Ther. 12, 261–265 (2007)
5. A. Bonjoch, M. Figueras, C. Estany, N. Perez-Alvarez, J. Rosales, L. del Rio, S. di Gregorio, J. Puig, G. Gómez, B. Clotet, E. Negredo, Osteoporosis Study Group, High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 24, 2827–2833 (2010)
6. M.J. Bolland, T.K. Wang, A. Grey, G.D. Gamble, I.R. Reid, Stable bone density in HAART-treated individuals with HIV: a meta-analysis. J. Clin. Endocrinol. Metab. 96, 2721–2731 (2011)
7. J. Huang, L. Meixner, S. Fernandez, J.A. McCutchan, A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 23, 51–57 (2009)
8. S. Rozenberg, E. Lanoy, M. Bentata, J.P. Viard, M.A. Valantin, P. Missy, I. Darasteanu, C. Roux, S. Kolta, D. Costagliola, ANRS 120 Fosivir Study Group, Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week Trial (ANRS 120). AIDS Res. Hum. Retrovir. 28, 972–980 (2012)
9. H. Taggart, M.A. Bolognese, R. Lindsay, M.P. Ettinger, H. Mulder, R.G. Josse, A. Roberts, H. Zippel, S. Adami, T.F. Ernst, K.P. Stevens, Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin. Proc. 77, 262–270 (2002)
10. R.A. Adler, Osteoporosis in men: recent progress. Endocrine 44, 40–46 (2013)
11. F. Cosman, Is there a role for combination therapy for osteoporosis? Endocrine 44, 5–7 (2013)
12. M.D. Walker, N.E. Cusano, J. Sliney Jr, M. Romano, C. Zhang, D.J. McMahon, J.P. Bilezikian, Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44, 237–246 (2013)
13. M. Caron-Debarle, C. Lagathu, F. Boccara, C. Vigouroux, J. Capeau, HIV-associated lipodystrophy: from fat injury to premature aging. Trends Mol. Med. 16, 218–229 (2010)
14. A. Sharma, P.L. Flom, J. Weedon, R.S. Klein, Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS 24, 2337–2345 (2010)
15. J. Pepe, M.T. Petrucci, M.L. Mascia, S. Piemonte, V. Fassino, E. Romagnoli, S. Minisola, The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcif. Tissue Int. 82, 418–426 (2008)
16. R. Iuliano, G. Forastieri, M. Brizzi, L. Mecocci, F. Mazzotta, L. Ceccherini-Nelli, HIV-plasma viral load detection by branched DNA signal amplification. New Microbiol. 18, 299–301 (1995)
17. J. Manasa, H. Musabaike, C. Masimirembwa, E. Burke, R. Luthy, J. Mudzori, Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe. Clin. Vaccine Immunol. 14, 293–298 (2007)
18. A. Aversa, R. Bruzziches, D. Francomano, G. Rosano, A.M. Isidori, A. Lenzi, G. Spera, Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged Men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind. J. Sex Med. 10, 3495–3503 (2010)
19. C.Y. Genant, C. van Wu, M.C. Kuijk, Nevitt, vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 9, 1137–1148 (1993)
20. M. Pedrazzoni, G. Girasole, F. Bertoldo, G. Bianchi, C. Cepollaro, A. Del Puente, S. Giannini, S. Gonnelli, D. Maggio, C. Marcocci, S. Minisola, E. Palummeri, M. Rossini, L. Sartori, L. Sinigaglia, Definition of a population-specific DXA reference standard in Italian Women: the densitometric Italian normative study (DINS). Osteoporos. Int. 14, 978–982 (2003)
21. I. Daig, L.A. Heinemann, S. Kim, S. Leungwattanakij, X. Badia, E. Myon, C. Moore, F. Saad, P. Potthoff, M. Thai do, The aging Males’ symptoms (AMS) scale: review of its methodological characteristics. Health Qual. Life Outcomes 15, 1–77 (2003)
22. J. Pepe, A.M. Isidori, M. Falciano, G. Iaiani, A. Salotti, D. Diacinti, R. Del Fiacco, E. Sbardella, C. Cipriani, S. Piemonte, E. Romagnoli, A. Lenzi, S. Minisola, The combination of frax and aging male symptoms scale better identifies treated Hiv males at risk for major fracture. Clin. Endocrinol. (Oxf) 77, 672–678 (2012)
23. O. Moreno-Pérez, C. Escoín, C. Serna-Candel, J. Portilla, V. Boix, R. Alfayate, V. González-Sánchez, M. Mauri, J. Sánchez-Payá, A. Picó, The determination of total testosterone and free testosterone (RIA) are not applicable to the evaluation of gonadal function in HIV-infected Males. J. Sex. Med. 7, 2873–2883 (2010)
24. K. Izumi, A. Mizokami, K. Sugimoto, K. Narimoto, S. Miwa, Y. Maeda, Y. Kadono, M. Takashima, E. Koh, M. Namiki, Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 73, 1342–1346 (2009)
25. E.G. de Menezes Barbosa, F.J. de Paula, A.A. Machado, F. de Assis Pereira, F. Barbosa Jr, A.M. Navarro, Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients. Bone 57, 62–67 (2013)
26. E. Orwoll, C.S. Teglbjærg, B.L. Langdahl, R. Chapurlat, E. Czerwinski, D.L. Kendler, J.Y. Reginster, A. Kivitz, E.M. Lewiecki, P.D. Miller, M.A. Bolognese, M.R. McClung, H.G. Bone, Ö. Ljunggren, B. Abrahamsen, U. Gruntmanis, Y.C. Yang, R.B. Wagman, S. Siddhanti, A. Grauer, J.W. Hall, S. Boonen, A randomized, placebo-controlled study of the effects of denosumab for the treatment of Men with low bone mineral density. J. Clin. Endocrinol. Metab. 97, 3161–3169 (2012)
27. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. New Engl. J. Med. 31, 604–610 (2000)
28. F. Zengerling, A.J. Schrader, M.V. Cronauer, H. Stemann, M. Schrader, L. Rinnab, The “aging Males’ symptoms” scale (AMS): predictive value for lowered circulating androgens. Aging Male 15, 253–257 (2012)
29. V. Carnevale, E. Romagnoli, C. Cipriani, R. Del Fiacco, S. Piemonte, J. Pepe, A. Scillitani, S. Minisola, Sex hormones and bone health in males. Arch. Biochem. Biophy. 503, 110–117 (2010)
30. A. Haider, U. Meergans, A. Traish, F. Saad, G. Doros, P. Lips, L. Gooren, Progressive improvement of T-scores in Men with osteoporosis and subnormal serum testosterone levels upon treatment with testosterone over six years. Int. J. Endocrinol. 2014, 496948 (2014)